34-36 A concern for patients with BM treated with antiangiogenic therapies has been intracranial hemorrhage (ICH).

34-36 对于接受抗血管生成疗法治疗的 BM 患，一个令人担忧的问题是颅内血 (ICH)。

Antiangiogenic agents have shown modest additional benefits when added to chemotherapy in both the first- and second-line settings, including in patients with BM.

在一线和二线治疗（包括 BM 患）将抗血管生成药物添加到化疗时，已显示的额外益处。

Combinations of EGFR-TKIs and other types of agents have been investigated in the first-line setting, such as antiangiogenic agents (bevacizumab and ramucirumab) combined with erlotinib.

EGFR-TKI 与其他类型药物的组合已在一线环境进行了研究，例如抗血管生成药物（贝伐珠单抗和雷莫芦单抗）与厄洛替尼的组合。